Opportunities for Healthy Volunteers
Contribute to medical research by participating in studies designed for healthy participants in your selected area.
↓
Matched clinical trials
Study of RMC-6291 with ivonescimab drug combination in patients with advanced RAS‑mutated solid tumors
Recruiting
Investigated Drugs:- (12M)-(1S,2S)-N-((63S,4S,Z)-11-ETHYL-12-(2-((S)-1-METHOXYETHYL)-5-(4-METHYLPIPERAZIN-1-YL)PYRIDIN-3-YL)-10,10-DIMETHYL-5,7-DIOXO-61,62,63,64,65,66-HEXAHYDRO-11H-8-OXA-2(4,2)-THIAZOLA-1(5,3)-INDOLA-6(1,3)-PYRIDAZINACYCLOUNDECAPHANE-4-YL)-2-METHYLCYCLOPROPANE-1-CARBOXAMIDE
- Rmc-6291
- (2S)-2-CYCLOPENTYL-2-[(5S)-2-[(2R,3R)-3-CYCLOPROPYL-1-METHYLAZIRIDINE-2-CARBONYL]-2,7-DIAZASPIRO[4.4]NONAN-7-YL]-N-[(6S,8S,14S)-21-[5-(4-CYCLOPROPYLPIPERAZIN-1-YL)-2-[(1S)-1-METHOXYETHYL]PYRIDIN-3-YL]-18,18-DIMETHYL-9,15-DIOXO-22-(2,2,2-TRIFLUOROETHYL)-5,16-DIOXA-2,10,22,28-TETRAZAPENTACYCLO[18.5.2.12,6.110,14.023,27]NONACOSA-1(26),20,23(27),24-TETRAEN-8-YL]ACETAMIDE
+3Zongertinib for Cancer in Patients Eligible for Early Access Treatment
Recruiting
Investigated Drugs:
Anti‑PD1 Therapy with pembrolizumab and cemiplimab in first‑line advanced non‑small cell lung cancer patients with high PD‑L1 expression
Recruiting
Investigated Diseases:Investigated Drugs:A study of YL201 and atezolizumab for patients with advanced solid tumors
Recruiting
Investigated Drugs: 
+2A study of DS-3790A, rituximab, and epcoritamab in patients with blood cancers
Recruiting
Investigated Drugs: Study of ECI830, ribociclib, and fulvestrant in patients with advanced hormone receptor positive, HER2-negative breast cancer and advanced solid tumors
Recruiting
Investigated Diseases:Investigated Drugs:
